TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32532059

Group type: EXPERIMENTAL
Intervention: Antimalarial agents (AMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32532097

Group type: EXPERIMENTAL
Intervention: H7N9 live attenuated influenza vaccine (LAIV) administered intranasally, two doses.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo administered intranasally, two doses.
Number of subjects: 40
Study: 32532225

Group type: EXPERIMENTAL
Intervention: Two-way messaging therapy
Number of subjects: 10718
Study: 32532226

Group type: EXPERIMENTAL
Intervention: Tobramycin (28-day on/off regime)
Number of subjects: 17
Study: 32532234

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine (four-dose series: primary three doses followed by a fourth dose approximately 18 months later)
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine (four-dose series)
Number of subjects: 1578
Study: 32532644

Group type: EXPERIMENTAL
Intervention: Agitated Blood-Saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Agitated Air-Saline
Number of subjects: 0
Study: 32532797

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 168
Study: 32532858

Group type: EXPERIMENTAL
Intervention: WEB treatment
Number of subjects: 61
Study: 32532991

Group type: EXPERIMENTAL
Intervention: Non-ischemic heart preservation (NIHP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Static cold preservation (SCS)
Number of subjects: 31
Study: 32533380

Group type: EXPERIMENTAL
Intervention: Polymyxin-B hemoperfusion (PMX-HP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 32533394

Group type: EXPERIMENTAL
Intervention: Presence of adolescents aged 15-19 in the household
Number of subjects: 705

Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 705
Study: 32533528

Group type: EXPERIMENTAL
Intervention: Indirect measurement of the respiratory exchange ratio (RER) using anaesthesia respirator; method not specified in detail.
Number of subjects: 0
Study: 32534242

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
Number of subjects: 77
Study: 32534455

Group type: EXPERIMENTAL
Intervention: Weight suppression
Number of subjects: 1165
Study: 32534583

Group type: EXPERIMENTAL
Intervention: Follow-up assessments after 1 year and 3 years
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Brain MRI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Brain cholinergic PET-imaging with fluoroethoxybenzovesamicol (FEOBV-PET)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Brain dopaminergic PET-imaging with fluorodopa (FDOPA-PET)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Detailed neuropsychological assessments
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Gut microbiome composition analysis
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intestinal wall permeability assessment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Genotyping
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Assessment of motor and non-motor symptoms
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lifestyle factors assessment including dietary assessment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Storage of blood and feces for additional analyses
Number of subjects: 150
Study: 32535123

Group type: EXPERIMENTAL
Intervention: Splanchnic nerve block (SNB) with ropivacaine
Number of subjects: 19
Study: 32535742

Group type: COMPARATOR
Intervention: U100 URLi
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: U200 URLi
Number of subjects: 68
Study: 32536445

Group type: EXPERIMENTAL
Intervention: Sevoflurane general anaesthesia
Number of subjects: 59
Study: 32536573

Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided radiation therapy (MRgRT)
Number of subjects: 101
Study: 32536880

Group type: EXPERIMENTAL
Intervention: TeleCoach™, a web-based skills training smartphone app
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 89
Study: 32536979

Group type: EXPERIMENTAL
Intervention: YYB101 (0.3, 1, 3, 5, 10, 20, 30 mg/kg) administered intravenously once every 4 weeks for 1 month, then once every 2 weeks until disease progression or intolerable toxicity
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: YYB101 (20 mg/kg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: YYB101
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: YYB101 + irinotecan
Number of subjects: 39
Study: 32536984

Group type: EXPERIMENTAL
Intervention: Stepwise tapering of rhTNFR:Fc
Number of subjects: 311

Group type: COMPARATOR
Intervention: Delayed tapering of rhTNFR:Fc
Number of subjects: 311

Group type: COMPARATOR
Intervention: Discontinuation of rhTNFR:Fc
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: rhTNFR:Fc 25 mg monthly
Number of subjects: 311
Study: 32537166

Group type: EXPERIMENTAL
Intervention: Higher LOX expression
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: LOX expression
Number of subjects: 683
Study: 32538690

Group type: EXPERIMENTAL
Intervention: Pazopanib (dosage and duration not available)
Number of subjects: 0
Study: 32539108

Group type: COMPARATOR
Intervention: USA cohort
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: The Netherlands cohort
Number of subjects: 1114
Study: 32539711

Group type: EXPERIMENTAL
Intervention: Digital programme
Number of subjects: 67

Group type: COMPARATOR
Intervention: Paper booklet
Number of subjects: 67
Study: 32539719

Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 0
Study: 32539729

Group type: EXPERIMENTAL
Intervention: Newborn Behavioral Observation (NBO)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Care as usual (comparison group)
Number of subjects: 196
Study: 32539738

Group type: EXPERIMENTAL
Intervention: Kinematic analysis of drinking task
Number of subjects: 56
Study: 32539744

Group type: EXPERIMENTAL
Intervention: Intravitreal injections of 0.5 mg ranibizumab under '1 + PRN' regimen
Number of subjects: 69
Study: 32539773

Group type: EXPERIMENTAL
Intervention: BLS and SERS spectroscopies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liquid Chromatography-Mass Spectrometry (LC-MS)
Number of subjects: 0
Study: 32539794

Group type: EXPERIMENTAL
Intervention: 2.7 g/day of DHA
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 2.7 g/day of EPA
Number of subjects: 122

Group type: COMPARATOR
Intervention: 3 g/day of corn oil (control)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Exclusion of participants with neutral TG responsiveness
Number of subjects: 122
Study: 32540647

Group type: EXPERIMENTAL
Intervention: Continuous motion monitoring based localization (Calypso) with initial localization, CBCT, pre-treatment motion correction by kV-imaging, and gating during irradiation (strategy A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Non-gated treatments (strategy B)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Non-gated and single image-guided (CBCT) localization (strategy C)
Number of subjects: 22
Study: 32540838

Group type: EXPERIMENTAL
Intervention: Tele-Exercise and Multiple Sclerosis (TEAMS) intervention, 12-week complementary and alternative medicine (CAM) intervention with 20 sessions of synchronous training sessions of dual tasking, yoga, and Pilates exercises.
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Teleassessment measures including resting blood pressure and heart rate, grip strength, Five Times Sit to Stand, Timed Up & Go, and the Berg Balance Scale.
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Posttraining period of 9 months of continued exercise as instructed.
Number of subjects: 759
Study: 32540851

Group type: EXPERIMENTAL
Intervention: FSP neoantigen vaccination
Number of subjects: 0
Study: 32540858

Group type: EXPERIMENTAL
Intervention: Tislelizumab 0.5, 2, 5 or 10 mg/kg every 2 weeks; 2 or 5 mg/kg every 2 or 3 weeks; or 200 mg every 3 weeks (Phase IA)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Tislelizumab 5 mg/kg every 3 weeks (Phase IB)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Tislelizumab (all doses)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks
Number of subjects: 451
Study: 32541189

Group type: EXPERIMENTAL
Intervention: Pentacam
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Galilei
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 906
Study: 32541292

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine 1.3% (266 mg, 20 mL) and bupivacaine hydrochloride 0.25% (52 mg, 20 mL)
Number of subjects: 30
Study: 32541385

Group type: EXPERIMENTAL
Intervention: Women with HIV on ART
Number of subjects: 34

Group type: COMPARATOR
Intervention: Women without HIV
Number of subjects: 34
Study: 32541391

Group type: EXPERIMENTAL
Intervention: Presurgical risk model based on 6 clinical predictors (surgical procedure, younger age, physical health, mental health, preoperative pain in the surgical field, preoperative pain in another area)
Number of subjects: 1088
Study: 32541565

Group type: EXPERIMENTAL
Intervention: Deceased donor uterus transplant (DD UTx)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Live-donor uterus transplant (not detailed in the abstract)
Number of subjects: 10
Study: 32542023

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPIs)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: High PPI dose (>20 mg omeprazole equivalents/day)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Low PPI dose
Number of subjects: 703

Group type: COMPARATOR
Intervention: No PPIs
Number of subjects: 703
Study: 32542089

Group type: EXPERIMENTAL
Intervention: TURBT
Number of subjects: 983
Study: 32542216

Group type: EXPERIMENTAL
Intervention: Massive PE
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Submassive PE
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: NRVD PE
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: SSO PE
Number of subjects: 1188
Study: 32542466

Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg daily for 8 weeks
Number of subjects: 32
Study: 32542468

Group type: EXPERIMENTAL
Intervention: Flortaucipir PET (injection of ~370 mBq flortaucipir, 20-min PET scan starting 80 min post-injection)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Flortaucipir PET
Number of subjects: 3
Study: 32542497

Group type: EXPERIMENTAL
Intervention: Prediabetes Decision Aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 32542577

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy initiated prior to sampling
Number of subjects: 56

Group type: COMPARATOR
Intervention: No prior antibiotic exposure
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 56
Study: 32542853

Group type: EXPERIMENTAL
Intervention: Qualiveen
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: SF-Qualiveen
Number of subjects: 189

Group type: COMPARATOR
Intervention: ICIQ-SF
Number of subjects: 189
Study: 32542873

Group type: EXPERIMENTAL
Intervention: Current use of antidepressants
Number of subjects: 63999

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 63999

Group type: EXPERIMENTAL
Intervention: Imipramine-type antidepressants
Number of subjects: 63999

Group type: EXPERIMENTAL
Intervention: Other or mixed antidepressants
Number of subjects: 63999
Study: 32542890

Group type: EXPERIMENTAL
Intervention: Airborne viral source strength measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indoor CO2 levels measurement
Number of subjects: 0
Study: 32542985

Group type: EXPERIMENTAL
Intervention: Klinefelter syndrome (KS) group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 32544032

Group type: EXPERIMENTAL
Intervention: Impaired reservoir strain (≤22%)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Impaired conduit strain (≤10%)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 321
Study: 32544223

Group type: EXPERIMENTAL
Intervention: Renal transplant recipients (RTRs)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Anal hrHPV positive RTRs
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Risk factors for anal HSIL in RTRs
Number of subjects: 247

Group type: COMPARATOR
Intervention: Immunocompetent controls
Number of subjects: 247
Study: 32544297

Group type: EXPERIMENTAL
Intervention: N8-GP prophylaxis 50 IU/kg every fourth day (Q4D)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: N8-GP prophylaxis 75 IU/kg once weekly (Q7D)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: N8-GP (all treatment arms)
Number of subjects: 186
Study: 32544491

Group type: EXPERIMENTAL
Intervention: Type 3 polygraphy using Somnolter
Number of subjects: 78
Study: 32545531

Group type: EXPERIMENTAL
Intervention: Red meat intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-grain intake
Number of subjects: 0
Study: 32545856

Group type: EXPERIMENTAL
Intervention: ILTHPI (Intraluminal Therapy for H. pylori Infection)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Normal acidity (pH < 4.0)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Low-level hypoacidity (pH 4.0-5.5)
Number of subjects: 324

Group type: COMPARATOR
Intervention: High-level hypoacidity (pH ≥ 6.0)
Number of subjects: 324
Study: 32546071

Group type: EXPERIMENTAL
Intervention: Blinatumomab (9-28-112 μg/day) in a 70-day cycle 1 and an optional 28-day cycle 2
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Blinatumomab (9-28-112 μg/day)
Number of subjects: 41
Study: 32546136

Group type: EXPERIMENTAL
Intervention: Genomic analysis, gut microbiota characterization, and behavioral phenotyping using the Recovery Record app for 30 days.
Number of subjects: 1000
Study: 32546275

Group type: EXPERIMENTAL
Intervention: Dietary linoleic acid (LA)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Circulating linoleic acid (LA)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Higher dietary linoleic acid (LA)
Number of subjects: 633
Study: 32546636

Group type: EXPERIMENTAL
Intervention: Aneurysm coiling for unruptured aneurysms
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Aneurysm coiling for ruptured aneurysms
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Incomplete aneurysm occlusion after initial treatment
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Complete aneurysm occlusion after initial treatment
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Dome-to-neck ratio with rebleeding
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Dome-to-neck ratio without rebleeding
Number of subjects: 1140
Study: 32546694

Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 31
Study: 32546951

Group type: EXPERIMENTAL
Intervention: Kaleidos case for the 2WIN infrared photoscreener
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: GoCheck Kids (GCK) with flash-concentrating case for iPhone 7 Plus
Number of subjects: 162

Group type: COMPARATOR
Intervention: Kaleidos compared to cycloplegic examination
Number of subjects: 162
Study: 32547188

Group type: EXPERIMENTAL
Intervention: Nanosomal docetaxel lipid suspension (NDLS) chemotherapy (75-100 mg/m2)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Nanosomal docetaxel lipid suspension (NDLS) chemotherapy
Number of subjects: 91
Study: 32547189

Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 33
Study: 32547210

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0
Study: 32547424

Group type: EXPERIMENTAL
Intervention: Wide-Rigid (WR) cuffs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Narrow-Elastic (NE) bands
Number of subjects: 15

Group type: COMPARATOR
Intervention: No bands (Control)
Number of subjects: 15
Study: 32547496

Group type: EXPERIMENTAL
Intervention: Vitrified blastocyst transfers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preparation protocols
Number of subjects: 0
Study: 32548285

Group type: EXPERIMENTAL
Intervention: BrICS-LIT platform with semiautomated tumor segmentation algorithms for T2-weighted FLAIR and contrast-enhanced T1-weighted MRI
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 20000
Study: 32548677

Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous Immunotherapy (SCIT)
Number of subjects: 0
Study: 32549995

Group type: EXPERIMENTAL
Intervention: 7-session manualised telephone-delivered intervention based on CBT principles plus information about fatigue
Number of subjects: 75

Group type: COMPARATOR
Intervention: Information only
Number of subjects: 75
Study: 32550738

Group type: EXPERIMENTAL
Intervention: Analgesic (Lidocaine hydrochloride 40 mg plus adrenaline 0.025 mg) with tenaculum replacement
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Analgesic (Lidocaine hydrochloride 40 mg plus adrenaline 0.025 mg) without tenaculum replacement
Number of subjects: 228

Group type: COMPARATOR
Intervention: No analgesic with tenaculum replacement
Number of subjects: 228

Group type: COMPARATOR
Intervention: No analgesic without tenaculum replacement
Number of subjects: 228
Study: 32550864

Group type: EXPERIMENTAL
Intervention: GDPT (gemcitabine, cisplatin, prednisone, thalidomide)
Number of subjects: 153

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: GDPT
Number of subjects: 153
Study: 32551134

Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula surgery
Number of subjects: 54

Group type: COMPARATOR
Intervention: Arteriovenous graft surgery
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Study-specific assessments
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Follow-up assessments
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Grip strength, functional independence, and vascular access satisfaction assessments
Number of subjects: 54
Study: 32551439

Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopic sclerotherapy with long injection needle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopic sclerotherapy with short injection needle
Number of subjects: 0
Study: 32551797

Group type: EXPERIMENTAL
Intervention: Okada Purifying Therapy
Number of subjects: 0
Study: 32552266

Group type: EXPERIMENTAL
Intervention: Canakinumab 4 mg/kg every 4 weeks for ≤48 weeks
Number of subjects: 19
Study: 32552278

Group type: EXPERIMENTAL
Intervention: Lack of health care provider HPV vaccine recommendation
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Perceived lack of insurance coverage for the HPV vaccine
Number of subjects: 955
Study: 32552299

Group type: EXPERIMENTAL
Intervention: Doll therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32552471

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 24 months
Number of subjects: 370
Study: 32552759

Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC)
Number of subjects: 500000
Study: 32552763

Group type: EXPERIMENTAL
Intervention: BC-Predict
Number of subjects: 18700

Group type: COMPARATOR
Intervention: Usual NHSBSP
Number of subjects: 18700
Study: 32552775

Group type: EXPERIMENTAL
Intervention: ReWalk ReStore™ soft robotic exosuit
Number of subjects: 44
Study: 32552778

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 0
Study: 32552828

Group type: EXPERIMENTAL
Intervention: Long endotracheal tube (LET)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aintree intubation catheter (AIC)
Number of subjects: 20
Study: 32552833

Group type: EXPERIMENTAL
Intervention: Implementation of a clinical information system embedded electronic order set for delivering evidence-based best practices.
Number of subjects: 0
Study: 32553024

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 0
Study: 32553027

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32553145

Group type: EXPERIMENTAL
Intervention: Kiwifruit consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no kiwifruit)
Number of subjects: 0
Study: 32553149

Group type: EXPERIMENTAL
Intervention: Ozanimod 1.0 mg oral capsule daily for 12 weeks (after 7-day dose escalation)
Number of subjects: 69
Study: 32553254

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 7203
Study: 32553333

Group type: EXPERIMENTAL
Intervention: DART (dissection and re-entry techniques) with SI (subintimal) stenting
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: DART with SI stenting
Number of subjects: 231
Study: 32554135

Group type: EXPERIMENTAL
Intervention: Group 1 (viscosity < 439 cP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Group 2 (viscosity > 439 cP)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 32554315

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel monotherapy (240 mg/m)
Number of subjects: 42
Study: 32554539

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) group
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-OSA group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination scores at 36 months
Number of subjects: 144
Study: 32554609

Group type: EXPERIMENTAL
Intervention: E7046 (125 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E7046 (250 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E7046 (500 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E7046 (750 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E7046 (all doses)
Number of subjects: 30
Study: 32554615

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg intravenously every 3 weeks (Q3W) in Group 3 (n=56)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg intravenously every 2 weeks (Q2W) in Group 1 (n=59)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 115
Study: 32554725

Group type: EXPERIMENTAL
Intervention: Electronic questionnaire for symptom monitoring
Number of subjects: 29
Study: 32554740

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) using a limited sampling strategy (t=0 and t=5 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Historical controls without TDM
Number of subjects: 100
Study: 32554800

Group type: EXPERIMENTAL
Intervention: Lobar ICH
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Non-lobar ICH
Number of subjects: 1094